Polyamine depletion by ODC-AdoMetDC antisense adenovirus impairs human colorectal cancer growth and invasion in vitro and in vivo

Journal of Gene Medicine

Volumn 8, Issue 8, 2006, Pages 980-989

  Zhang, Bing ^a   Liu, Xian Xi ^a   Zhang, Yan ^a   Jiang, Chun Ying ^b   Hu, Hai Yan ^a   Gong, Lei ^a   Liu, Min ^a   Teng, Qing Shan ^c  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Traditional Med University   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal cancer; Gene therapy; Ornithine decarboxylase; Polyamine; S adenosylmethionine decarboxylase; Tumor xenograft assay

Indexed keywords

ADENOSYLMETHIONINE DECARBOXYLASE; ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; ENHANCED GREEN FLUORESCENT PROTEIN; MATRIGEL; ORNITHINE DECARBOXYLASE; POLYAMINE; PUTRESCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER REGRESSION; CELL COUNT; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL LEVEL; CELL LINE; CELL STRAIN CACO 2; CELL STRAIN HT29; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DEPLETION; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC INHIBITION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE THERAPY;

ADENOSYLMETHIONINE DECARBOXYLASE; ANIMALS; ANIMALS, NEWBORN; BETA-GALACTOSIDASE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOMEGALOVIRUS; DEPENDOVIRUS; EVALUATION STUDIES; FACTOR IX; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDES, ANTISENSE; ORNITHINE DECARBOXYLASE; POLYAMINES; SEROTYPING; SEX FACTORS; TIME FACTORS; TISSUE DISTRIBUTION; TRANSGENES;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 33747830293     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.936     Document Type: Article

References (43)

1. Mattews HR. Polyamines, chromatin structure and transcription. BioEssays 1993; 15: 561-567.
2. Dandrifosse G, Deloyer P, Grandfils C, et al. Statement on polyamines. Rev Med Liege 1999; 54: 175-183.
3. Ahmad N, Gilliam AC, Katiyar SK, et al. A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol. 2001; 159: 885-892.
4. Holtta E, Sistonen L, Alitalo K. The mechanisms of ornithine decarboxylase deregulation in c-Ha-ras oncogene-transformed NIH 3T3 cells. J Biol Chem 1988; 263: 4500-4578.
5. Sistonen L, Holtta E, Lehvaslaiho H, et al. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase. J Cell Biol 1989; 109: 1911-1919.
6. Auvinen M, Paasinen A, Andersson LC, et al. Ornithine decarboxylase activity is critical for cell transformation. Nature 1992; 360: 355-358.
7. Paasinen-Sohns A, Kielosto M, Kaariainen E, et al. c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase. J Cell Biol 2000; 151: 801-810.
8. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent, Clin Cancer Res 1999; 5: 945-951.
9. Warrell RP Jr, Burchenal JH. Methylglyoxal-bis(guanylhydrazone) (methyl-GAG): current status and future prospects, J Clin Oncol 1983; 1: 52-65.
10. Regenass U, Mett H, Stanek J, et al. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 1994; 54: 3210-3217.
11. Eskens FA, Greim GA, van Zuylen C, et al. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Clin Cancer Res 2000; 6: 1736-1743.
12. Winawer SJ. Natural history of colorectal cancer. Am J Med. 1999; 106: 3S-6S; discussion 50S-51S.
13. Loser C, Folsch UR, Paprotny C, Creutzfeldt W. Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum and urine of 50 patients with colorectal cancer. Cancer 1990; 65: 958-966.
14. Higuchi CM, Wang W. Comodulation of cellular polyamines and proliferation: biomarker application to colorectal mucosa. J Cell Biochem 1995; 57: 256-261.
15. Sun AH, Liu XX, He QS, et al. Expression and clinical implication of ODC mRNA in colorectal carcinoma. Chin J Curr Adv Gen Surg 2004; 7: 150-152.
16. Hu HY, Liu XX, Zhang B, et al. Ornithine decarboxylase gene is overexpressed in colorectal carcinoma. World J Gastroenterol 2005; 11: 2244-2248.
17. Zhang Y, Liu XX, Zhang B, et al. Inhibition of prostate cancer cells with antisense RNA of ornithine decarboxylase gene. Chin J Biochem Mol Biol 2005; 21: 128-133.
18. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998, 95: 2509-2514.
19. Prevec L, Christie BS, Laurie KE, Bailey MM, Graham FL, Rosenthal KL. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immune Defic Syndr 1991; 4: 568-576.
20. Aboul-Enein HY, al-Duraibi IA. Separation of several free polyamines and their acetylated derivatives by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr 1998; 12: 291-293.
21. Bao Y, Peng W, Verbitsky A, et al. Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes. The Prostate 2005; 64: 401-407.
22. Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995; 11: 136-140.
23. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
24. Cohen SS. A Guide to the Polyamines, Oxford University Press: New York, 1998.
25. Love RR, Astrow SH, Cheeks AM, et al. Ornithine decarboxylase (ODC) as a prognostic factor in operable breast cancer. Breast Cancer Res Treat 2003; 79: 329-334.
26. Gutman M, Beltran PJ, Fan D, et al. Treatment of nude mice with 4-amidinoindan-1-one 2′-amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells. Melanoma Res 1995; 5: 147-154.
27. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: C212-221.
28. Hashimoto Y, Hibasami H, Tamaki S, et al. Induction of apoptotic cell death in human hepatocellular carcinoma SK-HEP-1 cells by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone). Anticancer Drugs 1999; 10: 323-327.
29. Nowels K, Homma Y, Seidenfeld J, et al. Prevention of inhibitory effects of alpha-difluoromethylornithine on rat urinary bladder carcinogenesis by exogenous putrescine. Cancer Biochem Biophys 1986; 8: 257-263.
30. Thompson HJ, Ronan AM. Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis 1986; 7: 2003-2006.
31. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986; 77: 1309-1313.
32. Arbeit JM, Riley RR, Huey B, et al. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV 16 transgenic mice. Cancer Res 1999; 59: 3610-3620.
33. Marton LJ, Pegg AE. Polyamines as targets for therapeutic intervention. Annu Rev Pharmacol Toxicol 1995; 35: 55-91.
34. Gamet L, Cazenave Y, Trocheris V, et al. Involvement of ornithine decarboxylase in the control of proliferation of the HT29 human colon cancer cell line. Effect of vasoactive intestinal peptide on enzyme activity. Int J Cancer 1991; 47: 633-638.
35. McCormack SA, Johnson LR. Putrescine uptake and release by colon cancer cells. Am J Physiol 1989; 256: G868-877.
36. Desiderio MA, Bergamaschi D, Mascellani E, et al. Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors. Br J Cancer 1997; 75: 1028-1034.
37. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003; 376: 1-14.
38. WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype. Cancer Res 2001; 61: 7754-7762.
39. Kubota S, Kiyosawa H, Nomura Y, et al. Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst 1997; 89: 567-571.
40. Kubota S, Yamada T, Kamei S, Seyama Y. Ornithine decarboxylase is directly involved in mouse mammary carcinoma cell invasion in vitro. Biochem Biophys Res Commun 1995; 208: 1106-1115.
41. Manni A, Washington S, Griffith JW, et al. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 2002; 19: 95-105.
42. Manni A, Badger B, Grove R, et al. Isolation and characterization of human breast cancer cells overexpressing S-adenosylmethionine decarboxylase. Cancer Lett 1995; 95: 23-28.
43. Ravanko K, Jarvinen K, Helin J, et al. Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts. Cancer Res 2004; 64: 8831-8838.